NeuroDerm Ltd. (NDRM) announced Wednesday morning that its Phase 2 trial of ND0612H met its primary, key secondary and additional secondary endpoints in patients with advanced Parkinson's disease.
from RTT - Before the Bell http://ift.tt/2mJ5csQ
via IFTTT
No comments:
Post a Comment